Cue Biopharma (NASDAQ:CUE) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Earnings and Valuation
This table compares Cue Biopharma and Theravance Biopharma's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cue Biopharma | $3.46 million | 101.23 | $-36,700,000.00 | ($1.66) | -6.93 |
Theravance Biopharma | $73.41 million | 18.26 | $-236,460,000.00 | ($4.25) | -4.84 |
Cue Biopharma has higher earnings, but lower revenue than Theravance Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Cue Biopharma and Theravance Biopharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cue Biopharma | -1,142.70% | -63.69% | -50.08% |
Theravance Biopharma | -345.16% | N/A | -51.60% |
Risk and Volatility
Cue Biopharma has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Cue Biopharma and Theravance Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cue Biopharma | 0 | 0 | 4 | 0 | 3.00 |
Theravance Biopharma | 0 | 0 | 7 | 0 | 3.00 |
Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Theravance Biopharma has a consensus price target of $33.2857, suggesting a potential upside of 61.97%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Theravance Biopharma.
Summary
Cue Biopharma beats Theravance Biopharma on 7 of the 13 factors compared between the two stocks.